Next-gen sequencing, mass spec to be used in PTSD consortium work

08/13/2013 | GenomeWeb Daily News (free registration)

The STRONG STAR Consortium to Alleviate PTSD, also known as the STRONG STAR-CAP, will use next-generation sequencing to look at structural contributors in diagnosing and treating PTSD, as well as mass spectrometry to discover protein biomarkers that could help predict PTSD risk. The consortium, led by the University of Texas Health Science Center in San Antonio, is receiving a $45 million grant from the Defense Department and Department of Veterans Affairs to support the research.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ